João Conde is a Group Leader and Professor at NOVA Medical School, Universidade Nova de Lisboa, ToxOmics. He received his PhD in Biology, specialty in NanoBiotechnology from the NOVA University and Universidad de Zaragoza in 2014, under the FP7 European Consortium NanoScieE+ – NANOTRUCK for the development of multifunctional gold nanoparticles for gene silencing. After, he was a Marie Curie Fellow at the Massachusetts Institute of Technology, Harvard-MIT Division for Health Sciences and Technology and in School of Engineering and Materials Science, Queen Mary University of London. From 2017 to 2019 he was a Junior Investigator at Instituto de Medicina Molecular. In 2019, he won an ERC Starting Grant to build a genetic biobarcode to profile breast cancer heterogeneity. He is also co-founder of the biotech company TargTex, Targeted Therapeutics for Glioblastoma Multiforme. Since 2020, he is also part of the Global Burden of Disease (GBD) Consortium from the Institute for Health Metrics and Evaluation (IHME), University of Washington.

The main aspects related to the recognition and diffusion of his early contributions are: more than 90 articles in journals of Cancer therapy, Materials Science and Biomedicine (The Lancet, Nature Materials, The Lancet Oncology, Nature Nanotechnology, JAMA Oncology, Nature Communications, The Lancet Gastroenterol Hepatol, PNAS, Accounts of Chemical Research, The Lancet Child Adolesc Health, Progress in Materials Science, ACS Nano, Advanced Materials, JACS, Angewandte Chemie, Advanced Functional Materials, Trends in Cancer, Trends in Biotechnology, Biomaterials, etc.), more than 30 articles are as 1st author and more than 45 articles as corresponding author and cited more than 8000 times (h-index 46). Several of them have been selected as cover page of journals such as Nature Nanotechnology (Covid-19 Special issue), The Lancet, The Lancet Oncology, ACS Nano, Adv. Functional Materials, Trends in Cancer, JACS, Angewandte Chemie, ACS Sensors, Biomaterials Science, ACS Applied Bio Mat, Adv. Healthcare Materials, Analytical & Bioanalytical Chemistry and BioTechniques. Moreover, 6 international patents were submitted and approved, all with relevant developments in nanomaterials-based platforms for cancer therapy and diagnosis. He was also awarded with several international awards, including the 2022 World’s Top 2% Scientists list by Stanford University, the Nanomaterials 2020 Young Investigator Award, the 2021 Biomaterials Science Emerging Investigators, the Top2% Most cited in Nanoscience/Nanotechnology from PLOS Biology, the Wellcome Image Awards 2017, the Nano-Micro Letters Researcher Award, and the National Cancer Institute Image award.

Conde Lab is focused on the application of multifunctional nano-and-biomaterials for cancer therapy and diagnosis, especially for tumour imaging and targeting, gene therapy/editing and drug delivery.